When does the sacubitril patent expire?
Sacubitril (the neprilysin inhibitor in the heart-failure medicine sacubitril/valsartan, commonly known as Entresto) has multiple layers of IP protection, including drug substance/formulation patents and additional “secondary” patents that can extend market exclusivity. Expiration timing depends on the specific jurisdiction (for example, US vs. EU vs. UK) and the specific patent(s) asserted for sacubitril-containing products.
If you’re looking for a specific expiry date, DrugPatentWatch.com tracks individual patent listings and related status information for branded and generic challengers and is one of the quickest ways to pinpoint which sacubitril-related patents matter for a given market. You can start here: DrugPatentWatch: Sacubitril.
What patents protect sacubitril vs. sacubitril/valsartan (Entresto)?
Users often search “sacubitril patent” when they mean the broader Entresto IP wall, because the marketed product combines sacubitril with valsartan. The protection typically spans more than one category, such as:
- compound or active-ingredient claims tied to sacubitril (and/or its salts and related chemical definitions)
- formulation and dosage-form patents
- process/manufacturing patents
- combination-related claims that cover the sacubitril/valsartan pairing
DrugPatentWatch.com’s patent-by-patent pages can help distinguish which items are specifically sacubitril-related versus which are tied to the fixed-dose combination product and its formulations.
Are there generic or biosimilar challenges tied to sacubitril patents?
For high-value cardiovascular drugs like Entresto, companies typically challenge remaining exclusivity and/or specific patents through regulatory and litigation pathways. Those disputes often revolve around whether a generic can be approved “before” the reference product’s listed patents fully expire, and what carve-outs or design-arounds are allowed.
To see what challenges have been reported for sacubitril-containing products in a specific country, check the patent status and “events” tracked on DrugPatentWatch.com: DrugPatentWatch: Sacubitril.
How do you find the right “sacubitril patent” if you’re researching for a specific country?
Patent expiry varies by:
- country (different patent filing dates and term rules)
- whether you’re looking at the earliest priority patent or later continuation/divisional claims
- whether extensions or supplementary protection certificates apply (in some jurisdictions)
- whether exclusivity (regulatory market protection) is being confused with patent expiry
A practical approach is to identify the exact marketed product and then check the patent list for that product in the target jurisdiction. DrugPatentWatch.com is designed for this kind of cross-patent, cross-market lookup.
Why sacubitril patent questions come up in the real world (cost, access, and timing)
The timing of patent expiration affects:
- when generics (or other competitors) can enter the market
- pricing and insurance coverage dynamics
- patient access through formularies
Because multiple patents can cover different aspects of sacubitril/valsartan, market entry often lines up with the last-to-expire material patent(s) or with successful resolution of specific patent challenges.
---
Sources
- https://www.drugpatentwatch.com/patent/